These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27144279)

  • 21. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tigecycline: an update.
    Stein GE; Babinchak T
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of tigecycline in the treatment of infections in light of the new black box warning.
    Dixit D; Madduri RP; Sharma R
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):397-400. PubMed ID: 24597542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tigecycline: in community-acquired pneumonia.
    McKeage K; Keating GM
    Drugs; 2008; 68(18):2633-44. PubMed ID: 19093704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
    Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization.
    Falagas ME; Metaxas EI
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):913-23. PubMed ID: 19803699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
    Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C
    Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections.
    Liebenstein T; Schulz LT; Viesselmann C; Bingen E; Musuuza J; Safdar N; Rose WE
    Pharmacotherapy; 2017 Feb; 37(2):151-158. PubMed ID: 27983753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia.
    Zhou Y; Xu P; Li H; Wang F; Yan H; Liang W; Xiang D; Zhang B; Banh HL
    Br J Clin Pharmacol; 2021 Jul; 87(7):2838-2846. PubMed ID: 33283892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
    Rubino CM; Forrest A; Bhavnani SM; Dukart G; Cooper A; Korth-Bradley J; Ambrose PG
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5180-6. PubMed ID: 20921315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline.
    Falagas ME; Karageorgopoulos DE; Dimopoulos G
    Curr Drug Metab; 2009 Jan; 10(1):13-21. PubMed ID: 19149509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.
    Purdy J; Jouve S; Yan JL; Balter I; Dartois N; Cooper CA; Korth-Bradley J
    Clin Ther; 2012 Feb; 34(2):496-507.e1. PubMed ID: 22249106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
    Bassetti M; McGovern PC; Wenisch C; Meyer RD; Yan JL; Wible M; Rottinghaus ST; Quintana A
    Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
    Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
    Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re-defining tigecycline therapy.
    De Rosa FG; Corcione S; Di Perri G; Scaglione F
    New Microbiol; 2015 Apr; 38(2):121-36. PubMed ID: 25915055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tigecycline: a review of a new glycylcycline antibiotic.
    Scheinfeld N
    J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tigecycline: place in therapy and important considerations.
    Garrelts JC; Schroeder T
    Am J Health Syst Pharm; 2006 Jul; 63(13):1233. PubMed ID: 16790574
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.
    Muralidharan G; Micalizzi M; Speth J; Raible D; Troy S
    Antimicrob Agents Chemother; 2005 Jan; 49(1):220-9. PubMed ID: 15616299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of tigecycline.
    French GL
    J Chemother; 2008 Oct; 20 Suppl 1():3-11. PubMed ID: 19036669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.